AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of -0.340–0.310 for the period, compared to the consensus EPS estimate of -0.370. The company issued revenue guidance of $285.0 million-$288.0 million, compared to the consensus revenue estimate of $284.9 million. AngioDynamics also updated its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Stock Up 12.4 %

Shares of AngioDynamics stock opened at $10.86 on Thursday. The company has a 50 day moving average price of $10.28 and a 200 day moving average price of $8.85. The firm has a market capitalization of $439.46 million, a P/E ratio of -1.93 and a beta of 0.56. AngioDynamics has a 52 week low of $5.47 and a 52 week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. During the same period in the prior year, the firm earned ($0.05) EPS. The firm’s revenue was down .1% on a year-over-year basis. As a group, research analysts anticipate that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

Insiders Place Their Bets

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.